Oligodeoxyribozymes that cleave β-catenin messenger RNA inhibit growth of colon cancer cells via reduction of β-catenin response transcription

Molecular Cancer Therapeutics

Volumn 9, Issue 6, 2010, Pages 1894-1902

  Choi, Bo Ra ^a   Gwak, Jungsug ^b   Kwon, Hyun Mi ^a   Oh, Sangtaek ^b   Kim, Kwang Pyo ^a   Choi, Woo Hyung ^a   Cho, Yo Han ^a   Kim, Dong Eun ^a  

^a Konkuk University   (South Korea)

^b Inje University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; MESSENGER RNA; OLIGODEOXYRIBOZYME; RIBOZYME; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER INHIBITION; COLON CANCER; DNA SEQUENCE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RNA INTERFERENCE;

BASE SEQUENCE; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DNA, CATALYTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; NUCLEIC ACID CONFORMATION; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC;

EID: 77953431049     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0056     Document Type: Article

References (29)

1. Collet JP, Sharpe C, Belzile E, Boivin JF, Hanley J, Abenhaim L. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 1999;81:62-8. (Pubitemid 29415492)
2. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000;103:311-20.
3. Morin PJ. β-Catenin signaling and cancer. Bioessays 1999;21:1021-30.
4. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
5. Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Hum Mol Genet 2001;10:721-33.
6. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-45. (Pubitemid 29519912)
7. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-12. (Pubitemid 28425575)
8. Tetsu O, McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6. (Pubitemid 29180374)
9. Takahashi M, Tsunoda T, Seiki M, Nakamura Y, Furukawa Y. Identification of membrane-type matrix metalloproteinase-1 as a target of the β-catenin/Tcf4 complex in human colorectal cancers. Oncogene 2002;21:5861-7. (Pubitemid 35007236)
10. Nath N, Kashfi K, Chen J, Rigas B. Nitric oxide-donating aspirin inhibits β-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear β-catenin-TCF association. Proc Natl Acad Sci U S A 2003;100:12584-9.
11. Gilmore TD, Koedood M, Piffat KA, White DW. Rel/NF-κB/IκB proteins and cancer. Oncogene 1996;13:1367-78.
12. Bours V, Bentires-Alj M, Hellin AC, et al. Nuclear factor-κB, cancer, and apoptosis. Biochem Pharmacol 2000;60:1085-9.
13. Deng J, Miller SA, Wang HY, et al. β-catenin interacts with and inhibits NF-κB in human colon and breast cancer. Cancer Cell 2002;2:323-34.
14. Dihlmann S, Klein S, Doeberitz Mv MK. Reduction of β-catenin/T-cell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated β-catenin. Mol Cancer Ther 2003;2:509-16.
15. Hawcroft G, D'Amico M, Albanese C, Markham AF, Pestell RG, Hull MA. Indomethacin induces differential expression of β-catenin, γ-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis 2002;3:107-14.
16. Roh H, Green DW, Boswell CB, Pippin JA, Drebin JA. Suppression of β-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells. Cancer Res 2001;61:6563-8.
17. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. Small interfering RNAs directed against β-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003;9:1291-300.
18. Santoro SW, Joyce GF. A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci U S A 1997;94:4262-6.
19. Kim K-S, Choi W-H, Gong S-J, Oh S, Kim J-H, Kim D-E. Efficient target site selection for an RNA-cleaving DNAzyme through combinatorial library screening. Bull Korean Chem Soc 2006;27:657-62.
20. Lima WF, Brown-Driver V, Fox M, Hanecak R, Bruice TW. Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. J Biol Chem 1997;272:626-38.
21. Matveeva O, Felden B, Audlin S, Gesteland RF, Atkins JF. A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures. Nucleic Acids Res 1997;25:5010-6.
22. Paterson BM, Roberts BE, Kuff EL. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc Natl Acad Sci U S A 1977;74:4370-4.
23. Dass CR, Choong PF, Khachigian LM. DNAzyme technology and cancer therapy: cleave and let die. Mol Cancer Ther 2008;7:243-51.
24. Breaker RR, Joyce GF. A DNA enzyme that cleaves RNA. Chem Biol 1994;1:223-9.
25. Cairns MJ, Hopkins TM, Witherington C, Wang L, Sun LQ. Target site selection for an RNA-cleaving catalytic DNA. Nat Biotechnol 1999;17:480-6. (Pubitemid 29217902)
26. Zeng G, Apte U, Cieply B, Singh S, Monga SP. siRNA-mediated β-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia 2007;9:951-9. (Pubitemid 350086440)
27. Micsenyi A, Tan X, Sneddon T, Luo JH, Michalopoulos GK, Monga SP. β-Catenin is temporally regulated during normal liver development. Gastroenterology 2004;126:1134-46. (Pubitemid 38451184)
28. Dvory-Sobol H, Sagiv E, Kazanov D, Ben-Ze'ev A, Arber N. Targeting the active β-catenin pathway to treat cancer cells. Mol Cancer Ther 2006;5:2861-71.
29. Conacci-Sorrell M, Zhurinsky J, Ben-Ze'ev A. The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest 2002;109:987-91. (Pubitemid 34408571)